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Abstract
Background: The links between dietary fat intake, polyunsaturated fatty acid intake and breast cancer risk remain
equivocal, with some studies pointing to improvements in risk upon omega-3 supplementation. However, the
background diet is poorly controlled in most studies, potentially confounding this link. Therefore, this study
examined the hypothesis that in order to see the benefits of omega-3 fatty acid supplementation, the background
diet must be low in fat.
Methods: Of the 56 healthy, pre-menopausal women randomized to one of two experimental arms, consisting of
a two-treatment, randomized, cross-over design, 41 completed the 10 month intervention. The two diet phases
(habitual and low-fat) were separated by a washout phase, each lasting 3 menstrual cycles. During each diet phase,
women were supplemented with 1.2 g eicosapentaenoic acid + docosahexaenoic acid per day.
Results: Red blood cell fatty acid composition indicated that more eicosapentaenoic acid and docosahexaenoic
acid was incorporated in the low-fat diet than the habitual diet, though both diet phases resulted in significant
increases in the omega-3 to omega-6 ratio. In the context of omega-3 supplementation in breast cancer risk
reduction, we also measured fatty acid incorporation into nipple aspirate fluid. Similar changes to red blood cells
were noted in nipple aspirate fluid, with higher incorporation of eicosapentaenoic acid in the low-fat diet phase.
Conclusions: These data suggest that the total level of dietary fat has some direct impact on fatty acid partitioning
in addition to the recognized importance of fatty acid ratios, and supports the hypothesis that dietary fat intake
must be considered a confounder in supplementation trials. Additionally, we demonstrate that n3 supplementation
both reaches and imparts improvements in lipid content and n3:n6 at the target breast tissue.
Trial registration: Trial was been retrospectively registered at clinicaltrials.gov (RegNCT02816125).
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Background
Dietary factors, specifically dietary fat, have been hy-
pothesized to account for the large variation in global
breast cancer incidence and the increases amongst
migrant populations [1, 2]. Support for an influence of
dietary fat on breast cancer rates has been demonstrated
in animal experiments [3, 4] and international correl-
ation studies [5, 6], however more recent data from co-
hort and case–control studies have been equivocal [7, 8].
Therefore, the potential link between dietary fat and risk
for breast cancer has been controversial for many years,
and continued research in this area has only raised more
unanswered questions. Recognizing the risk factors for
breast cancer permits the identification of women with
increased risk of developing the disease and the potential
for intervention to modify the risk both individually or
through population based approaches.
Specifically, experimental data has linked breast cancer
risk to a high dietary intake of n-6 polyunsaturated fatty
acids (PUFAs), particularly when associated with a low
intake of n-3 PUFAs [9]. Experimental animal models
support this with evidence that n-6 PUFAs enhance
breast tumourigenesis and metastasis, while in contrast,
n-3 PUFAs inhibit growth of initiated breast cancer cells
[9]. In addition to total PUFA amounts, dietary n-6 to n-
3 FA ratio (n-6:n-3; total omega-6 fatty acids in the diet
to total omega-3 fatty acids in the diet) has been associ-
ated with breast cancer risk [10–13] and breast cancer
risk has increased in Japanese women over the past four
decades correlating with a decrease in the dietary n-3:n-
6 PUFAs [14].
Despite compelling evidence relating dietary fat and
breast cancer from animal models, mechanistic experi-
ments in vitro and ecologic studies, these results are not
well supported by available epidemiologic data in
humans [15]. A pooled analysis of several cohort studies
did not find an association between dietary fat and
breast cancer [16]. Recently, the results of the Women’s
Health Initiative dietary modification trial demonstrate a
weak (non-significant) inverse association between a
low-fat diet and the risk of breast cancer [17]. These
conflicting results have led to uncertainty over the asso-
ciation of dietary fat and breast cancer and thus in nutri-
tional recommendation for breast cancer prevention
[18]. Several confounding variables may be responsible
for these conflicting results including: methodological is-
sues with regards to study design, measurement error,
improper statistical analysis, dietary assessment tools,
and a lack of heterogeneity of dietary fat intake of the
study participants [7].
More recent epidemiologic studies have attempted to
address some of the methodological limitations that
affected earlier studies through the use of validated
questionnaires, adjusting estimates for a wider range of
potential confounders and examining specific fatty acids
and their interrelationships [15]. Although the link be-
tween a low-fat diet and breast cancer prevention re-
mains controversial [19–21], the evidence is substantial
enough to support prospective studies and clinical trials
with the hypothesis that reduced intake of dietary fat will
decrease breast cancer risk [19, 22]. The current study
attempted to determine whether the n-3 incorporation
and n-3:n-6 was influenced by the level of total dietary fat
intake in a female population with a family history of
breast cancer. We hypothesized that the greatest improve-
ments in lipid profiles from n-3 supplementation would
occur in the condition of a low-fat diet background.
Methods
Participant recruitment and screening
This intervention study was approved by the Research
Ethics Board of the University of Guelph (REB235). Po-
tential participants were recruited between February and
August 2004 through newspaper advertisements, pam-
phlets and posters in doctors’ offices in Guelph, ON and
the surrounding community.
Potential participants were screened through a phone
or email questionnaire after which they were then given
a detailed oral and written outline of the study, answers
to frequently asked questions, and a 7-day screening
food record. Potential participants were deemed eligible
if they were healthy, premenopausal, eumenorrheic
women between 20 and 54 years of age who were sed-
entary or recreationally active, had a body mass index
(BMI) of 20–30 kg/m2 and a dietary fat intake of 30–40 %.
Exclusionary criteria included use of oral contraceptives
or hormone therapies; smoking; alcohol consumption
greater than 7 drinks per week; highly trained athletes;
pregnancy and/or lactation within the previous 6 months;
consumption of fish oil capsules within the previous
3 months; and the use of thyroid, hypertensive, oral
hypoglycemic or insulin therapy.
Once eligibility was established, participants gave in-
formed written consent and were oriented to the study
through an individual meeting with a study coordinator.
They were provided with a study handbook that in-
cluded detailed instructions outlining all study visits, a
study calendar according to menstrual cycle days, infor-
mation about the study supplements, materials to assist
with the low-fat diet phase of the study, instructions on
how to complete accurate food records, 7-day food rec-
ord forms, a study diary with instructions, and detailed
information about all study sample collections.
Experimental design
Of the 212 women originally screened, 56 met the eligi-
bility criteria and agreed to participate. These partici-
pants were randomized to one of two experimental
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arms, consisting of a two-treatment, randomized, cross-
over design (see Fig. 1). During the eligibility screening,
potential participants completed a questionnaire outlin-
ing their basic demographic characteristics, pregnancy
and breast-feeding history as well as family history of
breast cancer and other diseases. Subjects were given an
exit questionnaire upon the completion of the study.
The purpose of this questionnaire was to assess the
feasibility of the low-fat diet, and gain valuable informa-
tion about the nipple aspirate fluid extraction procedure,
subjects menstrual cycle patterns and the study supple-
ment. It also provided subjects with a means to express
any concerns or improvements they had with regard to
any aspect of the study.
Study diets and food records
There were two diet phases in the study separated by a
washout phase. Subjects were randomized to consume
either a low-fat diet or their habitual diet in Phase I.
After 3 menstrual cycles (MC) on the Phase I diet, the
subjects were asked to consume their habitual diet for 3
menstrual cycles, during which time no supplements
were consumed. The participants then crossed over to
the other experimental diet, Phase II (habitual or low-
fat) for an additional 3 menstrual cycles during which
supplement was again consumed.
During the low-fat diet phase, the target fat intake
was 20 % of energy or less. The exact quantity of total
fat was calculated individually for each participant
based on their 7-day habitual food record provided at
study entry. Food records were analyzed using ESHA
Food Processor (ESHA Research Version 7.11) to calcu-
late energy, total fat, saturated fat, monounsaturated
fat, polyunsaturated fat, carbohydrate, protein, dietary
fiber, vitamin and mineral intake. A daily fat intake rec-
ord was provided in the study handbook and filled out
each day by participants throughout the low-fat study
period. This served as a tool to aid with compliance to
the low-fat diet protocol and was reviewed at the
weekly nutrition counseling sessions.
Participants completed six 7-day food records through-
out the course of the study, including one pre-study
screen, three low-fat diet and two habitual diet food re-
cords. The food records were completed at different time
periods throughout the menstrual cycle to account for
possible alterations in food intake patterns. One of the
study coordinators contacted each participant individually
to provide reminders of when to commence the necessary
food records outlined in the study protocol. Food records
were analyzed immediately upon receipt by one of the two
study coordinators, one of whom was a registered diet-
ician or by one of two undergraduate research students
that were trained on the use of Food Processor.
Study supplements
During both the Phase I (MC1, MC2, MC3) and Phase II
(MC7, MC8, MC9) diet intervention periods, all partici-
pants consumed 4–500 mg fish oil capsules per day (SEE
YOURSELF WELL™ OMEGA-3 Dietary Supplement: See
Yourself Well Inc., Leamington, ON) containing 200 mg
of eicosapenaenoic acid (EPA) and 100 mg of docosahex-
aenoic acid (DHA) for a total of 1.2 g n-3/day. On the first
day of the fourth menstrual cycle, supplementation was
stopped and the participants resumed their habitual diet
for a three menstrual cycle washout period (MC4, MC5,
MC6). From the first day of their seventh menstrual cycle
(MC7), participants restarted the n-3 FA supplementation
for another 3 menstrual cycles. Possible side effects of the
supplement or diet intervention were discussed at each
nutritional counseling session. Supplement compliance
was assessed by counting unused capsules and confirmed
by analyzing red blood cell phospholipid fatty acid com-
position (see below).
Anthropometric measurements
At baseline, height was measured using a metric tape
measure (to nearest 0.5 cm) and body weight using a
digital scale (to the nearest 0.1 kg; ACCULAB® SV-100),
followed by calculation of BMI. During the study, mea-
surements were completed for body weight, body com-
position, blood pressure, waist and hip circumference
according to the schedule summarized in Table 1. Blood
pressure was taken on the left arm using an automated
cuff digital blood pressure monitor (LifeSource™ UA-767)
while the participant remained relaxed and seated. Waist
and hip circumference were measured using a flexible tape
measure (to the nearest 0.5 cm). The waist circumference
measurement was taken at the point of most noticeable
narrowing or an indeterminate waist was approximated by
taking the girth at the estimated lateral level of the twelfth
Fig. 1 Experimental design and participant flowchart. MC =menstrual
cycle
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or lower floating rib and the hip circumference measure-
ment was taken from the widest area of the hip. Body
composition was measured using bioelectric impedance
analysis (BIA; BodyStat 1500™) in hydrated, fasting partici-
pants, as described previously [23].
Blood collection and analysis
Blood was drawn by venipuncture, after a 12 h fast on
day 4, 5 or 6 of the menstrual cycle (for whole blood,
red blood cell, serum and plasma separation). In order
to minimize diurnal variation of reproductive hormones,
the time of blood draw was kept as consistent as pos-
sible within each participant. Whole blood and isolated
fractions were separated, aliquoted into multiple tubes
and stored frozen at −80 °C until analysis.
Serum samples were analyzed in triplicate for estradiol
(E2) levels using a competitive enzyme immunoassay
(EIA; Cayman Chemical, Ann Arbor, MI) according to
manufacturer’s instructions. Three separate analyses
were run over the course of the 1.5 years of the trial
period. At each point a lab-specific and assay kit control
sample was included to reduce inter-assay variability.
Red blood cells were obtained by removing white cells
and plasma/serum by centrifugation and stored at −80 °C
until analysis. Total red blood cell fatty acid composition
was analyzed by a commercial laboratory, Lipid Analytical
Labs (Guelph, ON), using a combination of lipid extrac-
tion and Gas Chromatographic techniques. Total lipid
was extracted according to the methods of Bligh and Dyer
[24]. The phospholipid and triglyceride fractions were
separated from other lipids by thin–layer chromatography
on silica Gel F Redi/Plates (Fisher, Unionville, ON) in a
solvent of heptane:isopropyl ether:acetic acid (60:40:3).
The origin, containing phospholipids, and the triglyceride
fraction were scraped after visualization with 0.1 % amino-
naphtholsulfonic acid, and fatty acids were methylated
after addition of the fatty acid 17:0 (3 μg) as an internal
standard. Methylated fatty acids were analyzed on a Varian
3400 gas–liquid chromatograph (Palo Alto, CA) with a
60-m DB-23 capillary column (0.32 mm internal diameter),
as previously described [25].
Urine collection and analysis
Participants collected the first void of the morning urine
samples on day 4, 5 or 6 (the morning of their study
visit) of menstrual cycles 1, 4, 6, and 9, and the begin-
ning and end of each treatment period. Participants were
provided with 3-l urine collection containers (VWR
International, Mississauga, ON) and a urine collection
hat (Norfolk Medical Supply, Guelph, ON) to place dir-
ectly over the toilet seat during urine collection. All
urine collection containers included a label, which out-
lined the urine collection protocol and provided space to
record the participant number, date and time of collec-
tion. The urine collection protocol required participants
to collect all urine produced during the first morning
void immediately after waking up, and if urination oc-
curred frequently throughout the night to collect all
voids after falling asleep and the subsequent first void of
the morning.
Participants were instructed to urinate directly into
the urine collection hat and then transfer all urine into
the collection container and store it in the refrigerator
until reporting for their study visit. Participants collected
urine in a fasted state and were instructed not to con-
sume alcohol for 24 h prior to urine collection. The time
of urine collection was kept consistent within each par-
ticipant to minimize diurnal variation of reproductive
hormones. Upon delivery, the total volume of urine and
collection date and time were recorded. The urine was
mixed with ascorbic acid (1 mg/mL of urine; Fisher Sci-
entific) to prevent oxidation of labile compounds, and
then aliquoted into four separate 15 mL conical tip
tubes (Starstedt, Montreal, QC) and frozen at −80 °C
for future analysis.
Urine samples were thawed and analyzed in triplicate
for 2-hydroxyestrone (2-OHE1) and 16-α-hydroxyestrone
(16-α-OHE1) using a competitive solid-phase enzyme
immunoassay (EIA, Immuna Care Corp, Bethlehem, PA).
Table 1 Data collection schedule of measurements
Treatment phase I Washout phase Treatment phase II
Menstrual cycle Menstrual cycle Menstrual cycle
1 2 3 4 5 6 7 8 9
Blood Sample + + + + + + + +
Body Weight + + + + + + + +
Blood Pressure + + + + + + + +
Waist: Hip + + + + + + + +
Body Composition + + + +
Urine Collection + + + +
Nipple Aspirate + + + +
+ Indicates measurement taken on day 4, 5 or 6 of corresponding menstrual cycle
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Lab-specific and assay kit control samples were included
in each kit in order to reduce inter-assay variability.
Nipple aspirate fluid collection and analysis
Nipple aspirate fluid (NAF) was collected on day 4, 5 or
6 (the morning of their study visit) of menstrual cycles
1, 4, 6, and 9, and at the beginning and end of each
treatment period, using a FirstCyte™ Aspirator (First-
Cyte™ Aspirator, Cytyc Health Corporation). The aspir-
ator consisted of a clear, rigid polycarbonate cup with
foam liner, attached to a 20 mL syringe which was used
to pull a gentle suction to express NAF using a modifi-
cation of techniques that have been described previously
[26, 27] and through direct communication via the tele-
phone with a researcher currently performing the pro-
cedure. Nipple aspiration took place in a private room
with participants relaxed and seated in a comfortable
upright position after cleaning, warming and gently mas-
saging the breast. The cup attached to the syringe was
placed directly over the centre of the nipple and suction
was applied by withdrawing the plunger of the syringe to
the 5–15 mL range, as tolerated, and held for 20 s or
until the participant experienced discomfort. If NAF did
not appear, the suction was repeated up to five times
until fluid was obtained. When NAF appeared, the aspir-
ator was carefully removed and the fluid droplets were
collected in capillary tubes. The entire procedure was re-
peated on the opposite breast. The NAF, contained
within capillary tubes, was stored in microcentrifuge
tubes and frozen at −80 °C for future analysis. When
NAF did not appear after five repeated attempts, the
procedure was repeated during the following (MC4)
study visit. If NAF was not produced after two separate
attempts, the participant was designated a non-secretor
and the procedure was discontinued. Of the women
who participated, only 45 % were able to provide suf-
ficient NAF for analysis. Of the entire cohort, 15 gave
sufficient material for fatty acid analysis at baseline,
during the low-fat supplement or the habitual supple-
ment phases (analyzed in the same manner as RBCs
described above).
Nipple aspirate samples were analyzed in triplicate for
estradiol levels using a competitive enzyme immuno-
assay (EIA; Cayman Chemical, Ann Arbor, MI) accord-
ing to manufacturer’s instructions. In some cases
samples were diluted in buffered saline to achieve con-
centrations within the standard curve. Because of the
different volumes of NAF collected from each partici-
pant, estradiol values were normalized to the protein
concentration of the NAF determined the method of
Bradford [28]. Because the NAF samples were all ana-
lyzed at the end of the trial, serum samples (from the
same participants, at the same time point in the trial)
were re-run at the same time to control for changes in
hormone levels with storage time. At each point a lab-
specific and assay kit control sample was included to
reduce inter-assay variability.
Statistical analysis
The anthropometric measurements and food records
were compared between baseline and after supplementa-
tion administration on both the low-fat and habitual di-
ets. Serum estradiol and urinary estrogen metabolic
ratios were analyzed using Analysis of Variance where
treatment and order were each predictor variables be-
cause of the cross-over design of the trial. These ana-
lyses indicated that there was no significant effect of
order and therefore this block was removed for all sub-
sequent analysis. Estradiol, urinary estrogen metabolites
and NAF fatty acid composition differences were ana-
lyzed by one-way ANOVA with repeated measures using
SPSS version 12 for Windows. FA profiles of red blood
cells in the low-fat diet with supplementation were com-
pared to baseline values by using a paired t-test (n = 41)
and differences between the two supplement phases by
paired t-test (n = 8). Differences were considered signifi-
cant when p < 0.05.
Results
Of the 56 participants randomized to one of the two
study arms, 47 actually began the study protocol with
the remaining 9 giving no reason for dropping out. Dur-
ing the subsequent 9–10 months, four participants were
removed from the study because of non-compliance
with the dietary protocol, one left for unknown reasons
and one withdrew because of pregnancy. Characteristics
of the 41 participants completed the intervention are
summarized in Table 2. The average age of the partici-
pants was 37.7 ± 1.4 years. Over 94 % of the participants
were Caucasian in ethnic origin and average BMI was
23.4 ± 0.4 kg/m2. To assess compliance to the study
protocol, 7-day diet records were periodically collected
and analyzed and capsules not consumed were recorded
at each study visit. Excellent compliance in consuming
the n-3 supplement during the two diet phases was ob-
served (~92 %; Table 3). The average menstrual cycle
length was 28.5 days (SD = 3.1) and was not different
between the habitual and low-fat diets (p = 0.82). Men-
strual cycle length ranged from 24 to 42 days meaning
that the supplementation period for each diet phase
could have been as few as 72 days and as many as
126 days. This is a very large potential difference in the
supplementation time but because of the small sample
size, no effect of cycle length was found when examining
the changes in fatty acid composition (see below).
The anthropometric measurements of 41 participants
taken at both the beginning and end of each interven-
tion period are shown in Table 4. After the low-fat diet
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phase, women had a significant reduction in: body
weight, BMI, waist circumference, hip circumference,
waist to hip circumference ratio and percentage body
fat. Following the habitual diet phase, weight and BMI
both significantly increased but there were no differ-
ences in other anthropometric measures.
There was no significant difference in total energy in-
take between the low-fat and habitual diet phases
(Table 5), despite the fact that a significant loss of body
weight was recorded during the low-fat phase. As ex-
pected, fat intake was lower and carbohydrate intake
higher in the low-fat versus the baseline or habitual diet
phases. On average, habitual fat intake was 35 % of calo-
ries and decreased to 22 % during the low-fat phase.
There were no significant differences in protein intake
between the low-fat and habitual phases suggesting that
the decreased fat intake was largely compensated for by
an increase in carbohydrate consumption. While there
were no significant differences in vitamins A or D intake
between the different diet phases, vitamin E intake was
significantly lower in the low-fat diet phase. Calcium in-
take was also similar between the diets. Before taking
into account supplementation, both n-3 and n-6 fatty
acid intake were significantly lower in the low-fat diet
compared to habitual diet, however, no difference was
found in the ratio of n-3 to n-6 fatty acids between these
two phases (Table 5). With 1200 mg of EPA plus DHA
in the supplements, the n-3 fatty acid (FA) intake from
all sources was significantly higher in both intervention
phases compared to the washout phase (1.86 g/d in low-
fat diet and 2.26 g/d in habitual diet vs. 1.06 g/d during
washout), and was accompanied by a significant increase
in the n-3:n-6 (Table 5).
The mean values of the individual FA phospholipid
(PL) moieties in red blood cell (RBC) membranes are
presented in Table 6. During the low-fat diet phase, n-3
supplementation resulted in a significant increase in
both DHA and EPA, and a significant decrease in ara-
chidonic acid (AA). The total unsaturated FA level sig-
nificantly increased from 38.0 to 40.1 %. Additional
significant changes in FA composition of RBC during
the low fat diet (LFD) phase included decreased 18:2n-
6, 20:2n-6, 20:3n-6, and 22:4n-6 as well as the long
chain saturated FA 22:0, long chain monounsaturated
fatty acids (MUFAs) 20:1, 22:1, 24:1 and increased
shorter chain MUFAs including C14:1, C16:1, C 18:1.
While many of the fatty acid changes observed in the
low-fat supplementation phase were mirrored in the
habitual supplement diet phase, there were some not-
able differences. In particular, DHA and EPA were
significantly lower in the habitual diet phase than that
observed in the low-fat intervention period. This re-
sulted in a significantly higher total percentage of n-3
in the LFD and a significantly higher ratio of n-3:n-6.
However, compared to the habitual diet without supple-
mentation, both supplementation periods resulted in
substantial decreases in total n-6, increases in n-3 and
dramatic improvements in the n-3:n-6 ratio (Fig. 2; 0.25
in habitual diet, 0.51 in low-fat supplement and 0.46 in
habitual supplement) and the ratio of AA:EPA (19.0 in
habitual diet, 4.8 in low-fat supplement and 5.3 in
habitual supplement).
The fatty acid composition of nipple aspirate total
phospholipids is shown in Table 7. There were a number
of small, but significant effects of supplementation on
NAF composition, demonstrating that supplementation
reached the target tissue. In particular, there was a de-
crease in AA in the habitual supplement phase and in
22:4n-6 in the low-fat supplement diet phase. Similar to
Table 2 Baseline characteristics of participants who completed
both phases of the study protocol
Mean ± SE Range
Age (years) 37.7 ± 1.4 20–54
Body weight (kg) 64.1 ± 1.5 46.6–83.7
Body Mass Index, BMI (kg/m2) 23.4 ± 0.4 18.9–29.9










Age at first live birth (years) 26.9 ± 4.6 19–38
Family history of breast cancer
Yes (%) 63.3
No (%) 36.7
Family history of hypertension
Yes (%) 56.1
No (%) 43.9
Table 3 Compliance to study omega-3 fatty acid supplements
Missed capsules/MC Missed days/MC Compliancea p-value
(n ± SE) (n ± SE)
Low-fat diet
phase
8.3 ± 3.5 2.1 ± 0.9 92.5 % 0.88
Habitual diet
phase
8.9 ± 2.0 2.3 ± 0.5 91.8 %
acompliance was calculated
as [(# capsules dispensed − # capsules returned)/capsules dispensed] × 100 %
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the changes in RBC fatty acids, there were significant in-
creases in both EPA and DHA in the supplement phases
compared to the habitual phase without supplementa-
tion. Again the increase in EPA was significantly larger
in the low-fat diet phase compared to the habitual sup-
plement phase. This resulted in a significant increase in
n-3:n-6 ratio in both supplement phases and similar de-
creases in the AA:EPA ratios (Fig. 3). However, there
were substantial differences in the major fatty acids of
NAF PL compared to RBC PL. For example, C14:0 rep-
resented approximately 0.4 % of RBC PL and 9 % in
NAF. Total saturated fatty acids were similar between
tissues (approximately 40 %), but MUFAs represented
45 % in NAF and only 22 % in RBC PL and PUFAs 15 %
in NAF and 40 % in RBC PL.
In an attempt to correlate improvements in lipid pro-
files to changes in biomarkers of breast cancer risk,
estradiol (E2), 2-hydroxyestrone (2-OHE1) and 16-α-
hydroxyestrone (16-α-OHE1) were measured. Serum E2
results showed significant decreases in both the low-fat
and habitual supplement phases as well as the washout
phase, compared to baseline (Fig. 4A). There were no
differences in NAF E2 at any intervention point or the
washout (Fig. 4B). Despite similarities in the pattern of
E2 levels in serum and NAF, when serum and NAF sam-
ples from the same participants were directly compared
Table 4 Measures of participants before and after the low-fat and habitual diet phases
Low-fat diet phase Habitual diet phase
(Mean ± SE; n = 41) (Mean ± SE; n = 41)
Before After p1 Before After p2
Body Weight (kg) 63.5 ± 1.4 61.7 ± 1.3 <0.001 62.2 ± 1.3 63.3 ± 1.3 <0.001
BMI (kg/m2) 23.4 ± 0.5 22.7 ± 0.4 <0.001 22.9 ± 0.4 23.4 ± 0.4 <0.001
Waist (cm) 76.2 ± 1.1 74.6 ± 1.0 <0.001 75.8 ± 1.0 76.3 ± 1.0 0.93
Hip (cm) 101.0 ± 1.0 99.4 ± 0.9 <0.001 100.2 ± 1.1 101.3 ± 0.9 0.44
Waist:Hip 0.76 ± 0.05 0.75 ± 0.04 <0.05 0.75 ± 0.004 0.75 ± 0.04 1.0
Body fat (%) 30.2 ± 0.8 28.6 ± 0.8 <0.001 29.8 ± 0.9 30.3 ± 0.8 0.68
Lean mass (%) 18.9 ± 0.5 19.0 ± 0.5 NS 19.3 ± 0.5 19.3 ± 0.4 1.0
p1, significance using a paired t-test before vs. after low-fat diet. p2, significance of the paired t-test before vs. after habitual diet
Table 5 Average daily intake of nutrients in the low-fat diet and habitual diet phases (n = 38a)
Habitual diet Low-fat diet p-value
(Mean ± SE; n = 38a) (Mean ± SE; n = 38)
Energy (kcal) (diet alone)b 1884 ± 42 1761 ± 41 0.17
Energy (kcal) (diet + supplement)c 1902 ± 45 1790 ± 26 0.22
Carbohydrate (g) 240 ± 7 269 ± 11 <0.05
Protein (g) 77 ± 3 79 ± 2 0.58
Fat (g) (diet alone) 66 ± 2 39 ± 2 <0.01
Fat (diet + supplement) 68 ± 2 42 ± 2 <0.01
Fat total (% energy) 35.7 ± 0.8 22.4 ± 0.5 <0.01
Vitamin A (IU) 4796 ± 583 4137 ± 585 0.43
Vitamin E (mg) 10.0 ± 0.9 7.4 ± 0.5 <0.05
Vitamin D (IU) 204 ± 21 201 ± 19 0.92
Calcium (mg) 937 ± 61 850 ± 45 0.41
n-3 FAs (g) (diet alone) 1.06 ± 0.08 0.64 ± 0.05 <0.01
n-3 FAs (g) (diet + supplement) 2.26 ± 0.08 1.86 ± 0.07 <0.01
n-6 FAs (g) 7.0 ± 0.5 4.7 ± 0.4 <0.01
n-3:n-6 (diet alone) 0.15 ± 0.02 0.14 ± 0.02 0.37
n-3:n-6 (diet + supplement) 0.32 ± 0.02 0.40 ± 0.03 0.11
p-value, paired t-test between habitual diet and low-fat diet; athree participants had incomplete food records; bDiet alone, cFood record analyzed from dietary
source without supplement. Diet + supplement, Food record analyzed from diet and DHA-EPA supplement
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there was no correlation between the serum value and
the NAF value, regardless of the time point of study
(Fig. 4C). The ratio of 2-OHE1 to 16-α-OHE1 was
significantly lower in the low-fat supplement period
compared to the washout and habitual supplement
phases, however this was not significantly different from
baseline (Fig. 5).
Discussion
This dietary intervention study was designed to examine
the impact of n-3 FA supplementation, in the context of
a low-fat compared to a higher-fat habitual diet, on the
FA profile in healthy pre-menopausal women. Our hy-
pothesis was that a long chain n-3 FA supplement (rich
in DHA and EPA) would have a larger effect on lipid
Table 6 Fatty acid composition (% by weight) in red blood cell membranes
Baseline (mean ± SE) Low-fat diet (mean ± SE) p1 Habitual diet (mean ± SE) p2
(n = 41) (n = 41) (n = 8)
C14:0 0.38 ± 0.07 0.36 ± 0.07 0.84 0.40 ± 0.04 0.81
C14:1 0.23 ± 0.18 0.39 ± 0.07 <0.01 0.45 ± 0.14 0.35
C15:0 0.22 ± 0.04 0.20 ± 003 0.69 0.19 ± 0.03 0.56
C16:0 23.59 ± 1.31 23.71 ± 1.44 0.95 22.6 ± 1.31 0.60
C16:1 0.22 ± 0.07 0.30 ± 0.10 <0.01 0.32 ± 0.04 0.24
C18:0 12.15 ± 0.81 12.04 ± 0.85 0.92 14.07 ± 0.51 <0.05
C18:1 17.04 ± 1.07 17.44 ± 1.25 <0.05 18.68 ± 0.43 0.18
C18:2n-6 12.20 ± 1.53 10.56 ± 2.13 <0.01 10.56 ± 0.86 0.36
C18:3n-6 0.04 ± 0.04 0.04 ± 0.03 1.0 0.03 ± 0.02 1.0
C18:3n-3 0.19 ± 0.06 0.18 ± 0.06 0.91 0.22 ± 0.06 0.73
C18:4n-3 0.02 ± 0.02 0.02 ± 0.02 1.0 0.10 ± 0.02 <0.05
C20:0 0.20 ± 0.15 0.16 ± 0.07 0.81 0.05 ± 0.02 <0.05
C20:1 0.31 ± 0.14 0.23 ± 0.07 <0.01 0.23 ± 0.04 0.59
C20:2n-6 0.13 ± 0.12 0.02 ± 0.02 <0.01 0.21 ± 0.06 <0.05
C20:3n-6 1.43 ± 0.34 1.25 ± 0.27 <0.01 1.34 ± 0.23 0.83
C20:4n-6 (AA) 12.96 ± 1.28 11.98 ± 1.55 <0.01 12.16 ± 1.21 0.66
C20:3n-3 0.01 ± 0.02 0.01 ± 0.01 1.0 0.01 ± 0.01 1.0
C20:4n-3 0.05 ± 0.04 0.05 ± 0.03 1.0 0.05 ± 0.05 1.0
C20:5n-3 (EPA) 0.80 ± 0.35 2.64 ± 0.62 <0.01 2.27 ± 0.4 P < 0.05
C22:0 1.15 ± 0.31 0.76 ± 0.19 <0.05 0.00 ± 0.00 <0.01
C22:1 0.99 ± 1.00 0.44 ± 0.16 <0.01 0.43 ± 0.33 0.60
C22:2n-6 0.10 ± 0.07 0.10 ± 0.04 1.0 0.00 ± 0.00 <0.01
C22:4n-6 3.08 ± 0.59 2.39 ± 0.53 <0.01 2.11 ± 0.44 0.21
C22:5n-6 0.33 ± 0.26 0.38 ± 0.66 0.94 0.02 ± 0.03 0.26
C22:5n-3 2.25 ± 0.44 3.74 ± 0.72 <0.01 3.70 ± 0.46 0.07
C22:6n-3 (DHA) 4.37 ± 1.09 6.91 ± 1.03 <0.01 6.08 ± 1.04 <0.05
C24:0 1.74 ± 1.30 1.89 ± 1.33 0.94 1.47 ± 0.16 <0.01
C24:1 3.78 ± 2.42 1.93 ± 0.45 <0.01 2.59 ± 0.46 <0.05
Saturated 39.44 ± 2.30 39.12 ± 1.71 0.91 38.75 ± 1.81 0.82
MUFA 22.58 ± 3.13 20.73 ± 1.48 0.59 21.04 ± 1.41 <0.05
PUFA 37.97 ± 2.71 40.13 ± 2.61 <0.01 39.94 ± 2.95 0.63
n-3 7.63 ± 1.61 13.57 ± 1.96 <0.01 12.03 ± 1.62 <0.05
n-6 30.20 ± 2.38 26.40 ± 2.14 <0.01 26.41 ± 1.90 0.23
n-3:n-6 0.25 ± 0.02 0.51 ± 0.02 <0.01 0.46 ± 0.007 <0.05
AA/EPA 19.01 ± 7.77 4.86 ± 1.74 <0.01 5.30 ± 1.04 0.10
Data are expressed as a percentage of total fatty acids ± standard error. p1, significance of paired t-test of baseline vs. after low-fat diet, p2, significance of paired
t-test of after low-fat diet vs. after habitual diet
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profiles when provided in the background of a low-fat
diet. Fatty acids were examined in both the standard
marker, red blood cells, as well as in nipple aspirate fluid
to provide a measure of the changes at the target tissue.
Study participants, as shown in Table 1, were repre-
sentative of a healthy pre-menopausal population of
women. However, this group was atypical in that a sub-
stantial proportion of them had a family history of breast
cancer (63 %), which is much higher than has been
reported in other studies (12.5 % [29]). This observation
may have contributed to the high level of compliance
observed in the current study despite the fact that it was
a lengthy protocol with minimal financial compensation.
Thus, while a family history was likely a motivating fac-
tor for participation and compliance, it may limit the
generalizability of the results.
Compliance with the low-fat dietary phase was very
important in this study. Therefore, continuous 7-day
food records were monitored to evaluate compliance.
Since participants did not know in advance which re-
cords would be collected for detailed analysis, this limits
the likelihood that they changed their eating behaviour
at specific time points other than those specified in the
study design. In total, three 7-day food records were
used to examine habitual diet and three for low-fat diet
phases. Compared to other food information collection
approaches, this is a reliable and valid approach [30].
The process of recording also served to remind the par-
ticipants to control their fat intake effectively. Analysis
of the food records indicated that the participants came
very close to the goal of 20 % dietary fat (22 % achieved)
during the low-fat intervention period, resulting in a net
decrease of 37 % dietary fat from their habitual diets. On
average, women were consuming 39 g of fat during
the low-fat diet phase, which is similar to the typical
Japanese diet we were aiming to mimic (31 g; [31]).
In the exit survey, only 2 participants indicated that
the low-fat diet was particularly difficult to adhere to.
To the contrary, most of the participants showed
good tolerance to the low-fat diet and expressed a
preference to consume a lower-fat diet in the future,
instead of their habitual diet. Though participants
were compliant, it is unlikely that the levels of DHA
and EPA provided by the supplement, could have
been easily replaced with dietary sources. This would
have required that fatty fish be consumed at 3–5
times per week, and a major change in the diet pat-
tern. Thus we would suggest that supplements would
be the best choice for achieving these kinds of
changes in membrane lipids at target tissues.
Compliance with the n-3 FA supplementation was also
excellent with over 90 % consumption of the supple-
ments provided. Consultation with the participants and
examination of their diaries indicated very few side effects
associated with either the dietary changes or supplement
use. We do not have data to indicate whether the women
indeed followed either the low-fat diet or continued with
fish oil supplement use after study cessation.
The present study showed that a low-fat diet supple-
mented with n-3 caused a significant decrease in body
weight, BMI, percent body fat, waist circumference, hip
circumference, waist to hip ratio. Interestingly, body
weight and BMI increased following the habitual diet
Fig. 2 Omega-3 and omega-6 content in red blood cells. a Omega-3
(n = 41), b omega-6 (n = 8) and c n-3:n6 content in red blood cell
membrane phospholipids. Data are expressed as a percentage of
total fatty acids ± standard error. a = significantly different from
baseline, b = significantly different from low fat diet phase by
paired t-test (p < 0.05)
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with supplementation. While statistically there were no
differences in total energy between the low-fat and ha-
bitual diets, there is significant error in estimating daily
energy intake, and small differences may have been ob-
scured by the large SDs. Thus it is possible that esti-
mating energy intake was a less sensitive indicator
using the methods herein, than absolute change in body
weight over the three-menstrual cycle period (approxi-
mately 3 months). It is also possible that there were
changes in physical activity or other behaviours as a
result of the additional attention being given to the
participants during the low-fat diet phase, despite the
fact that they were being counselled not to change any
other of their habits. Alternatively, the change in
macronutrient composition associated with the low-fat
diet may have resulted in increased energy expenditure,
leading to a weight loss in these participants as has
been reported before [32].
Table 7 Fatty acid composition of NAF phospholipids1,2
Baseline (mean ± SE; n = 15) Low fat diet (mean ± SE; n = 15) Habitual diet (mean ± SE; n = 15)
C14:0 10.02 ± 1.37 9.12 ± 0.86 8.83 ± 1.06
C14:1 0.32 ± 0.05 0.31 ± 0.08 0.31 ± 0.06
C15:0 1.65 ± 0.51a 1.29 ± 0.35b 1.38 ± 0.35b
C16:0 18.15 ± 2.81 21.0 ± 1.17 21.98 ± 1.07
C16:1 5.03 ± 0.99a 4.20 ± 0.78b 4.71 ± 1.20ab
C18:0 8.4 ± 0.33 8.29 ± 0.63 9.04 ± 1.01
C18:1 39.1 ± 1.9a 37.66 ± 1.46b 37.11 ± 1.03b
C18:2n-6 11.6 ± 1.4 11.93 ± 1.62 10.12 ± 0.98
C18:3n-6 0.01 ± 0.01 0.03 ± 0.01 0.08 ± 0.03
C18:3n-3 1.03 ± 0.17a 0.65 ± 0.14b 0.79 ± 0.19ab
C18:4n-3 0.008 ± 0.008a 0.11 ± 0.10b 0.06 ± 0.04b
C20:0 0.51 ± 0.10 0.57 ± 0.14 1.14 ± 0.41
C20:1 0.72 ± 0.14 0.82 ± 0.19 1.22 ± 0.27
C20:2n-6 0.29 ± 0.06 0.22 ± 0.06 0.25 ± 0.07
C20:3n-6 0.32 ± 0.07a 0.58 ± 0.16b 0.47 ± 0.16b
C20:4n-6 AA 0.94 ± 0.19a 1.21 ± 0.38ab 0.52 ± 0.17b
C20:3n-3 0.03 ± 0.01 0.05 ± 0.04 0.03 ± 0.01
C20:4n-3 0.04 ± 0.02 0.03 ± 0.01 0.03 ± 0.01
C20:5n-3 EPA 0.06 ± 0.03a 0.42 ± 0.20c 0.18 ± 0.06b
C22:0 0.18 ± 0.04a 0.12 ± 0.05b 0.21 ± 0.12a
C22.1 0.26 ± 0.09 0.22 ± 0.08 0.28 ± 0.10
C22:2n-6 0.003 ± 0.002 0.05 ± 0.03 0.003 ± 0.003
C22:4n-6 0.08 ± 0.03a 0.04 ± 0.01b 0.09 ± 0.03a
C22:5n-3 0.09 ± 0.03a 0.16 ± 0.05b 0.19 ± 0.05b
C22:6n-3 DHA 0.19 ± 0.05a 0.47 ± 0.11b 0.42 ± 0.14b
C24:0 0.50 ± 0.14a 0.22 ± 0.08b 0.06 ± 0.03c
C24:1 0.64 ± 0.18a 0.23 ± 0.08b 0.51 ± 0.26ab
Saturated 39.18 ± 2.74a 40.62 ± 1.47ab 42.64 ± 2.33b
MUFA 46.04 ± 2.61a 43.45 ± 1.93b 44.13 ± 1.77b
PUFA 14.78 ± 1.59 15.93 ± 2.14 13.23 ± 1.23
Total n-3 1.45 ± 0.24a 1.88 ± 0.31c 1.69 ± 0.41b
Total n-6 13.32 ± 1.52 14.05 ± 1.90 11.54 ± 0.98
n-3:n-6 0.11 ± 0.02a 0.13 ± 0.01b 0.14 ± 0.03b
AA/EPA 2.04 ± 0.98a 1.50 ± 0.37b 1.64 ± 0.59b
1Fatty acids are reported as mol % of total fatty acids in phospholipids ± Standard Error of the mean
2Values in a row not sharing a letter are significantly different (p < 0.05) by ANOVA followed by Tukey's post-hoc test
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Before participants entered the intervention phase of
the study, the fatty acid profile of RBC membranes was
analyzed and again after the low-fat diet in all partici-
pants and in a random smaller sample of participants
after the habitual supplement phase. Because there were
no differences in the fatty acid composition of RBCs in
Group 1 versus Group 2 participants, we conclude that
the three menstrual cycle washout was sufficient to
normalize their fatty acid levels before the second inter-
vention period. Given the very large changes in n-3 FA
composition in all participants, this gave a secondary in-
dication of compliance along with the capsule count.
Baseline distribution of the main fatty acids in RBC
membranes in our study, were similar to that reported
in a German cross-section study, which examined the
association between allergic sensitization with n-3
PUFAs in the diet and in RBC membrane composition
[33]. The baseline distribution was also similar to an-
other American study based on a healthy population in
Arizona [34]. However, the present study differs from a
Swedish cohort study [35] examining postmenopausal
women. The latter showed higher DHA and EPA levels,
lower AA and a higher n-3:n-6 ratio, than those ob-
served in the present study. One possible reason for this
discrepancy could be baseline differences in FA con-
sumption, or differences in menopausal status. Alterna-
tively, these two groups may have had other differences
in eating habits or other lifestyle factors (i.e. exercise)
that could affect FA metabolism.
In the present study, DHA levels in RBC membranes
were elevated by 58 % and EPA levels by 230 % following
n-3 supplementation in the background of the low-fat
diet (39 g/d). A decrease in AA was also observed but to
a lesser extent (7.5 %) than for the long-chain PUFAs. In
a similar randomized trial conducted by Geppert et al.
[36] examining DHA supplementation alone (0.94 g
DHA/d for 8 weeks) in vegetarians, DHA total FAs were
increased, whereas EPA levels rose only marginally with
no change in AA levels. The larger increase in EPA
levels in the present study suggests that the change in
EPA composition results from direct replacement of
some membrane AA from the supplemental EPA pro-
vided (800 mg) as opposed to retroconversion of DHA
to EPA and subsequent incorporation. The small change
in AA observed here (12.96 ± 1.28 vs. 11.98 ± 1.55) is
consistent with the study by Yuen and coworkers
(13.2 vs. 11.5; [34]) (31). Review of several human
studies [37, 38] suggests that supplementation with
various EPA and DHA preparations produces a rise in
AA concentrations when the total dose of EPA and
DHA is relatively small, and that the commonly reported
fall in AA concentration occurs only when the cumulative
amount of EPA and DHA administered is high. The lon-
ger duration of supplementation (3 months) and relatively
high dose of n-3 FAs (1.2 g/d), likely produced the AA
decrease shown in our study.
Although both n-3 and n-6 FA intake from food
sources were decreased in the low-fat diet compared to
the habitual diet with supplementation (1.06 ± 0.47 vs.
0.64 ± 0.33 in n-3 FAs; 7.03 ± 2.84 vs. 4.69 ± 2.38 in n-6
FAs), no significant difference in the ratio of n-3 to n-6
FAs (0.51 ± 0.02 vs. 0.46 ± 0.007) was observed between
these to experimental arms. This suggests that vegetable
and other oils were removed from the diet rather than
Fig. 3 Omega-3 and omega-6 content in nipple aspirate fluid. a
Omega-3, b omega-6 and c n-3:n-6 (n = 15) content in nipple aspirate
fluid. Data are expressed as a percentage of total fatty acids ± standard
error. a = different from baseline, b = different from LFD+ supplement
by ANOVA and Tukey's post-hoc test (p < 0.05)
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being substituted with other versions. Hence, the signifi-
cant increase in n3:n-6 detected in RBC membrane can
be specifically attributed to the n-3 FA supplement.
Additionally, there was a consistent increase in the pro-
portion of DPA (22:5n–3) in RBC membranes during
both supplement periods. This suggests a possible up-
regulation of elongase in response to the n-3 rich fatty
acid supplementation. Because EPA can be converted
into DPA by elongase, increased level of EPA from sup-
plementary source provided more substrate for this
metabolism.
To our knowledge, we are the first to report the effects
of n-3 supplementation on nipple aspirate fluid. Our
data demonstrate that n-3 supplementation has a direct
effect on NAF, with increases in n-3 s and improvements
in the n3:n6 ratio similar to that seen in RBCs. This in-
dicates that the supplement is reaching its target tissue
and therefore could be modulating its beneficial effects
at the tissue of interest. As seen with RBCs, the increase
in EPA and total n-3 s was also significantly higher on
the background of a LFD in NAF.
Interestingly, despite the fact that the n-3:n-6 FA ratios
were not significantly different between the low-fat sup-
plemented and habitual supplemented diet phases in ei-
ther RBCs or NAF, there were significant differences in
the pools of these FAs, with the low-fat diet showing
Fig. 4 Blood serum and NAF estrogen levels. 17-β-estradiol was measured by radioimmunoassay at baseline and 3 MC after each intervention or
washout period. a Average E2 levels ± SE in serum (n = 41). b Average E2 levels ± SE in NAF expressed per μg protein (n = 15). c correlation between
serum and NAF E2 concentrations. Points represent the serum E2 value plotted as a function of the corresponding NAF value. a = different from
baseline by ANOVA and Tukey's post-hoc test (p < 0.05)
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enhanced incorporation of n-3 FAs compared to the ha-
bitual diet. This suggests that the total level of fat in the
diet has some direct impact on fatty acid partitioning
in addition to the recognized importance of fatty acid
ratio. A similar study to detect the effect of a low-fat
diet on FA composition in RBCs found that FA pro-
file responded more to a low-fat diet than a habitual
diet [39]. It was also reported that n-6 FAs in RBCs
were increased significantly following a low-fat diet
intervention compared with a habitual diet. However,
with the n-3 FAs supplements, our study showed no
difference in total n-6 FA percentages between the low-
fat and habitual diets. This inconsistency suggests that n-3
FAs supplementation could modify the FA profiles to a
greater extent in the background of a low-fat diet. A
mechanism to explain this differential partitioning re-
mains unknown.
Although the functional roles of different RBC phos-
pholipids may not be well known, we do know that
changes in FA composition affect cell function [40], and
therefore could potentially impact breast cancer devel-
opment. Thus it is reasonable to predict that the FA
stores in breast tissue may be similarly altered which
could be reflected in the changes in NAF FA compos-
ition we observed; consequently, the breast cancer risk
may be reduced. Indeed, in a recent study in men under-
going prostatectomies, n3 supplementation was demon-
strated to favourably affect n3, n6 and n3:n6 in the
prostate tissue, mirroring changes in RBC membrane PL
content [41].
In an attempt to demonstrate an improvement in
markers of breast cancer risk following the various arms
of this study, metabolites of estrogen were measured. A
positive correlation between serum estrogens and breast
cancer risk in post-menopausal women is fairly well
established [42, 43], but this is not the case for pre-
menopausal women. Some association has been reported
in pre-menopausal breast cancer [44], including one pro-
spective study which found a positive association [45]
while in five others there was no significant association
between circulating estrogen levels and breast cancer
risk [42]. Additionally, the ratio of urinary 2-OHE1 to
16-α-OHE1 as a breast cancer risk marker has been sug-
gested [46], however a recent review found only a weak
positive association between this ratio and breast cancer
risk in pre-menopausal but not post-menopausal popula-
tions. We observed a significant decrease in serum E2
from baseline during both supplementation periods as
well as during the washout. While 3 months is usually
considered sufficient to "washout" red blood cell fatty
acids, it is not clear whether this is sufficient time to re-
establish baseline hormone levels, that could potentially
take much longer. There were no significant changes in
NAF E2 concentrations despite changes in FA compos-
ition in this tissue. There was also no correlation be-
tween serum and NAF E2 concentrations suggesting
that changes could occur in one compartment without
occurring in the other. The suggestion has been made
that the NAF (or other tissue of breast origin) is a better
place to measure biomarkers of breast cancer risk, particu-
larly estrogen metabolites [42] and it is quite possible that
urinary or circulating concentrations of estrogen metabo-
lites may not be good surrogate biomarkers. However, our
very low success rate with recovering NAF, despite having
well-trained and dedicated personnel to collect it, and very
good participant compliance with the procedure, suggests
Fig. 5 Relative concentrations of urinary estrogen metabolites 2-OHE1 and 16α-EOE1. Complete morning voids were collected on the same day
of the menstrual cycle each month. Portions were frozen at −80 °C until analysis. Freshly thawed samples (n = 34) were thawed and estimates of
metabolites determined by ELISA as described in the Methods. Values are in arbitrary units (ratio) ± SE. a = significantly different from LFD + supplement
(p< 0.05) by ANOVA followed by Tukey's post-hoc test
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that substitution of NAF for serum for routine screening,
is not practical. Furthermore, until the at-risk metabolic
profile (possibly achieved through more recent proteomic
methods [47–49]) can be determined, there will be little
opportunity to determine whether diet or other lifestyle
factors have the ability to affect risk at the tissue level.
Conclusions
We have shown that the influence of long-chain n-3
fatty acids on tissue FA composition is affected by the
total fat level in the diet; low-fat diets are associated with
better incorporation of DHA and EPA than traditional
Western diets. Importantly, we have demonstrated that
these improvements are measurable in a surrogate of
the target tissue, nipple aspirate fluid. Although others
[50, 51] have suggested that there are no positive asso-
ciations between fat intake or specific fatty acid intake
and breast cancer, is important to note that there were
very few participants consuming a very low-fat diet in
one [50], and a small range in intake of fatty acids in
the other [51]. We would argue that the potential bene-
fits of long-chain n-3 fatty acids can only be realized in
the background of a low-fat diet and at levels of supple-
mentation that most closely represent the traditional
Japanese diet, where better correlations between diet
and breast cancer risk has been identified [8, 36]. We
did see a significant decrease in circulating estrogen
levels with supplementation and this could be associated
with a decreased cancer risk in these pre-menopausal
women, consistent with some previous studies. There was,
however, no decrease in NAF hormone levels and thus it is
possible that any benefit of the n-3 fatty acids is occurring
through a mechanism unrelated to NAF E2. Omega-3 fatty
acids can act on a number of metabolic pathways and
newer metabolomic and proteomic approaches may be
able to identify more appropriate candidate biomarkers.
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